Loading chat...
US HB7837
Bill
Status
Introduced
3/5/2026
Primary Sponsor
Dan Meuser
Click for details
AI Summary
- Requires the Center for Medicare and Medicaid Innovation to test a "Most Favored Nations Pricing Model" beginning January 1, 2029, running for 5 years
- Mandates drug manufacturers provide Medicare Part B, Part D, and Medicaid beneficiaries access to the second-lowest net price charged in 8 reference countries: Canada, Denmark, France, Germany, Italy, Japan, Switzerland, and the United Kingdom
- Allows manufacturers to avoid mandatory participation by entering voluntary "covered agreements" with the Secretary by December 31, 2028, which must include commitments to increase U.S. manufacturing operations
- Applies to drugs sold in at least 2 reference countries, with pricing calculated using average prices paid to manufacturers after all rebates, discounts, and concessions, adjusted for purchasing power differences
- Introduced March 5, 2026 by Rep. Meuser and referred to the House Energy and Commerce Committee and Ways and Means Committee
Legislative Description
Most Favored Patient Act of 2026
Last Action
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
3/5/2026
Committee Referrals
Energy And Commerce3/5/2026
Full Bill Text
No bill text available